

Sepsivac (Repurposed Drug) and ACQH Phytopharmaceutical formulation - for COVID-19 Mitigation

Sepsivac

- Pre-trial clinical studies have **demonstrated safety in COVID-19** patients
- Phase II trials on critically ill COVID-19 patients
- Trials at PGI Chandigarh; AIIMS Delhi, and AIIMS, Bhopal.
- Approval for Phase-III trials in place: one on 600 patients, another on 500 patients.
- **Results expected soon**

ACQH- Phytopharmaceutical Formulation

- DCGI approval for clinical trials.
- **First-ever approval in India in phytopharmaceutical route**
- Clinical trials being done by **Sun Pharma** in collaboration with ICGEB & CSIR-IIIM Jammu India.
- Clinical trials on at 12 centers; in 210 patients
- **Results expected soon**



CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM)
Jammu, India

#CSIRFightsCOVID19